Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors

Area of Science:

• Immunotherapy
• Oncology
• Molecular Biology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy faces challenges in targeting solid tumors due to a lack of tumor-specific antigens.
• On-target, off-tumor CAR T-cell activation can lead to severe toxicities, limiting therapeutic applications.

Purpose of the Study:

• To develop a stringent hypoxia-sensing CAR T-cell system for selective targeting of solid tumors.
• To overcome the limitations of CAR T-cell therapy in solid malignancies by enhancing tumor selectivity and safety.

Main Methods:

• Engineered CAR T-cells with a hypoxia-sensing system to achieve selective CAR expression within the tumor microenvironment.
• Utilized murine xenograft models to evaluate the anti-tumor efficacy and toxicity profile of the hypoxia-sensing CAR T-cells.

Main Results:

• Demonstrated selective expression of a pan-ErbB-targeted CAR within solid tumors, characterized by hypoxic conditions.
• Achieved significant anti-tumor efficacy in murine models without observable off-tumor toxicity, despite ErbB receptor expression in healthy organs.

Conclusions:

• The hypoxia-sensing CAR T-cell system acts as a dynamic on/off safety switch, enabling targeted therapy in solid tumors.
• This approach has the potential to expand the repertoire of CAR T-cell targets for treating various solid malignancies safely and effectively.